

## **PrEParing for success: An intervention to increase HIV** prevention awareness among Internal Medicine residents

#### INTRODUCTION

- utilizi is a strategy antiretroviral medications to redu HIV transmission amongst at-ri individuals
- The purpose of this qua improvement project was to increa Internal Medicine (IM) residen knowledge and prescribing of PrEF

#### METHODS

- An anonymous paper survey w administered to IM residents at a suburban, community hospital Hudson Valley, NY in Summer 20 academic half-day during ambulatory block rotation
- The survey consisted of questic about residents' demographics, Pr knowledge, and previous prescribi of PrEP
- Participants were then given a 1-ho lecture by the authors on sexu PrEP includi history and indications, available options, dosi monitoring, side effects, and acce to therapy
- **1** 6 months later the survey w reissued to the residents
- Results analyzed were using descriptive statistics

Mario A. Torres, MD, Hector Ojeda-Martinez, MD, Valerie Cluzet, MD, MSCE, Rebecca Mazurkiewicz, MD, MPH

Vassar Brothers Medical Center, Poughkeepsie, NY USA

### RESULTS

| ng  | All 74 eligible residents   | S CC     |
|---|---|----------|
| lce   | survey  |          |
| isk   | □ 35 (47.3%) identified as female   | mal      |
| lity  | Medical school graduation   | vea      |
| ase   | General General Science of Complete Completed the second secon | J        |
| nts'  | While there were impro  | •        |
| $\supset$   | identify which medicati   |          |
|   | effective PrEP is at reduci   |          |
|   | how to initiate PrEP;   |          |
|   | improvement in participa  |          |
| vas   | questions (see Table)   |          |
| our   | The number of participar  | nts v    |
| in  | increased from 2 (2.7%) to  |          |
|   |   | <b>`</b> |
| 021   |   |          |
| 021<br>of   | S   | urvey    |
|   | S   | urvey    |
|   |   | urvey    |
| of  | St<br>Case 1. Initiating PrEP   | urvey    |
| of<br>ons   |   | urvey    |
| of<br>ons<br>rEP  | Case 1. Initiating PrEP<br>Case 2. Undetectable=Untransmissable<br>1. How often should someone who is taking PrEP be  | urvey    |
| of<br>nEP<br>ing  | Case 1. Initiating PrEP<br>Case 2. Undetectable=Untransmissable<br>1. How often should someone who is taking PrEP be<br>screened for HIV?<br>2. What laboratory tests must be checked prior to  | urvey    |
| of<br>ons<br>rEP<br>ing                                   | Case 1. Initiating PrEP<br>Case 2. Undetectable=Untransmissable<br>1. How often should someone who is taking PrEP be<br>screened for HIV?   | urvey    |
| of<br>nEP<br>ing  | Case 1. Initiating PrEP<br>Case 2. Undetectable=Untransmissable<br>1. How often should someone who is taking PrEP be<br>screened for HIV?<br>2. What laboratory tests must be checked prior to<br>initiating PrEP?<br>3. PrEP provides protection against HIV as well as which<br>one of the following?   |          |
| of<br>ons<br>rEP<br>ing                                   | Case 1. Initiating PrEP<br>Case 2. Undetectable=Untransmissable<br>1. How often should someone who is taking PrEP be<br>screened for HIV?<br>2. What laboratory tests must be checked prior to<br>initiating PrEP?<br>3. PrEP provides protection against HIV as well as which  | urvey    |
| of<br>nEP<br>ing<br>our<br>al<br>ing                      | Case 1. Initiating PrEP<br>Case 2. Undetectable=Untransmissable<br>1. How often should someone who is taking PrEP be<br>screened for HIV?<br>2. What laboratory tests must be checked prior to<br>initiating PrEP?<br>3. PrEP provides protection against HIV as well as which<br>one of the following?<br>4. How effective is PrEP at reducing the risk of   |          |
| of<br>ons<br>rEP<br>ing<br>our<br>al<br>ing<br>ng,<br>ess | Case 1. Initiating PrEP<br>Case 2. Undetectable=Untransmissable<br>1. How often should someone who is taking PrEP be<br>screened for HIV?<br>2. What laboratory tests must be checked prior to<br>initiating PrEP?<br>3. PrEP provides protection against HIV as well as which<br>one of the following?<br>4. How effective is PrEP at reducing the risk of<br>contracting HIV through IV drug use?<br>5. How effective is PrEP at reducing risk of contracting<br>HIV through sex?<br>6. How long must a person take PrEP to be maximally  |          |
| of<br>nEP<br>ing<br>ual<br>ing<br>ng,                     | Case 1. Initiating PrEP<br>Case 2. Undetectable=Untransmissable<br>1. How often should someone who is taking PrEP be<br>screened for HIV?<br>2. What laboratory tests must be checked prior to<br>initiating PrEP?<br>3. PrEP provides protection against HIV as well as which<br>one of the following?<br>4. How effective is PrEP at reducing the risk of<br>contracting HIV through IV drug use?<br>5. How effective is PrEP at reducing risk of contracting<br>HIV through sex?   |          |

ompleted the pre-intervention

le and 40 (52.7%) identified as

nr ranged 2007 to 2021

ost-survey

nents in participants' ability to are classified as PrEP, how transmission of HIV via sex, and nere was not a significant knowledge on the other survey

who reported prescribing PrEP

10%) after the intervention

#### v Results





# Nuvance Health

#### CONCLUSIONS

This educational intervention did not improve long-term knowledge retention of amongst participants However, there Was а substantial increase in number of residents who prescribed PrEP • One limitation is the short time frame between the

intervention and post-survey These findings demonstrate the need for early introduction of PrEP into medical school and residency program curricula

#### REFERENCES

1) Eisinger RW, Fauci AS. Ending the HIV/AIDS Pandemic1. Emerg Infect Dis. 2018 Mar;24(3):413-416. doi: 10.3201/eid2403.171797. PMID: 29460740; PMCID: PMC5823353.

2) Simon V, Ho DD, Abdool Karim Q. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet. 2006 Aug 5;368(9534):489-504. doi: 10.1016/S0140-6736(06)69157-5. PMID: 16890836; PMCID: PMC2913538.

3) Spinner CD, Boesecke C, Zink A, Jessen H, Stellbrink HJ, Rockstroh JK, Esser S. HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans. Infection. 2016 Apr;44(2):151-8. doi:

10.1007/s15010-015-0850-2. Epub 2015 Oct 15. PMID:

4) Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O'Reilly KR, Koechlin FM, Rodolph M, Hodges-Mameletzis I, Grant RM. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016 Jul

31;30(12):1973-83. doi: 10.1097/QAD.000000000001145. PMID: 27149090; PMCID: PMC4949005.

